SynthesisBMC surgery2025
Does pathological complete response after neoadjuvant chemoradiotherapy associate with long-term survival in esophageal cancer: A systematic review and meta-analysis.
Synthesis in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy.International journal of cancer · 2026Article
- A logNII-based model for predicting pathological complete response following neoadjuvant therapy in esophageal squamous cell carcinoma: a retrospective single-center study.World journal of surgical oncology · 2026Article
- Article
- Immunotherapy-based adjuvant treatment after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma according to pathological response.Frontiers in immunology · 2026Article
- Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma.Journal of translational medicine · 2025Article
- The neoadjuvant esophageal score: a prognostic tool for predicting survival and postoperative complications in esophageal squamous cell carcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveNeoadjuvant chemoradiotherapy (NCRT) combined with surgery has emerged as a crucial therapeutic approach for locally advanced esophageal cancer. However, the effectiveness of pathological complete response (pCR) as a short-term surrogate endpoint remains unclear. This meta-analysis aimed to investigate whether pCR significantly influences the long-term survival of patients with locally advanced esophageal cancer following NCRT combined with surgery.
methodsA systematic literature search was conducted in February 2024. The inclusion criteria encompassed resectable esophageal cancer cases that had received preoperative chemotherapy, radiation therapy, or chemoradiotherapy as neoadjuvant treatment. Random-effects or fixed-effects model was applied, and heterogeneity was quantified using Higgins' I
resultsThirty-eight articles were included. The meta-analysis demonstrated that pCR was associated with improved long-term survival following NCRT combined with surgery in patients with esophageal cancer (OS: HR = 0.54, 95%CI 0.52-0.57, DFS: HR = 0.51, 95%CI 0.46-0.57). Furthermore, a subgroup analysis revealed that patients achieving pCR exhibited a greater survival benefit compared to those who did not, when stratified by histology [squamous cell carcinoma or adenocarcinoma] (OS: HR
conclusionPCR after NCRT was significantly associated with the long-term survival prognosis of esophageal cancer. The findings of this meta-analysis suggest that pCR may serve as a surrogate endpoint for evaluating the survival outcomes of NCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.